Skip to content

Food Consumer

FDA granted tentative approval to Matrix Laboratories' fixed-dose abacavir, lamivudine and zidovudine tablet for treating HIV-1 in adults. Patent rights bar US marketing, but the tablet becomes eligible for purchase under PEPFAR, and fixed-dose tablets cut pill burden and may aid adherence.

1 min read

13770 stories